Boston Scientific Corp (BSX)vsEdwards Lifesciences Corp (EW)
BSX
Boston Scientific Corp
$56.50
+0.62%
HEALTHCARE · Cap: $83.97B
EW
Edwards Lifesciences Corp
$83.98
+0.57%
HEALTHCARE · Cap: $48.42B
Smart Verdict
WallStSmart Research — data-driven comparison
Boston Scientific Corp generates 227% more annual revenue ($20.61B vs $6.30B). EW leads profitability with a 17.4% profit margin vs 17.3%. BSX appears more attractively valued with a PEG of 0.68. BSX earns a higher WallStSmart Score of 71/100 (B).
BSX
Strong Buy71
out of 100
Grade: B
EW
Buy61
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-23.3%
Fair Value
$46.11
Current Price
$56.50
$10.39 premium
Margin of Safety
+69.9%
Fair Value
$263.84
Current Price
$83.98
$179.86 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Earnings expanding 100.0% YoY
Large-cap with strong market position
Growing faster than its price suggests
Strong operational efficiency at 20.6%
Generating 1.0B in free cash flow
Strong operational efficiency at 31.2%
16.7% revenue growth
Areas to Watch
No major concerns identified
Expensive relative to growth rate
Weak financial health signals
Premium valuation, high expectations priced in
Comparative Analysis Report
WallStSmart ResearchBull Case : BSX
The strongest argument for BSX centers on EPS Growth, Market Cap, PEG Ratio. Profitability is solid with margins at 17.3% and operating margin at 20.6%. Revenue growth of 11.6% demonstrates continued momentum.
Bull Case : EW
The strongest argument for EW centers on Operating Margin, Revenue Growth. Profitability is solid with margins at 17.4% and operating margin at 31.2%. Revenue growth of 16.7% demonstrates continued momentum.
Bear Case : BSX
No major red flags identified for BSX, but monitor valuation.
Bear Case : EW
The primary concerns for EW are PEG Ratio, Piotroski F-Score, P/E Ratio. A P/E of 45.4x leaves little room for execution misses.
Key Dynamics to Monitor
BSX profiles as a mature stock while EW is a growth play — different risk/reward profiles.
EW carries more volatility with a beta of 0.94 — expect wider price swings.
EW is growing revenue faster at 16.7% — sustainability is the question.
BSX generates stronger free cash flow (1.0B), providing more financial flexibility.
Bottom Line
BSX scores higher overall (71/100 vs 61/100), backed by strong 17.3% margins and 11.6% revenue growth. EW offers better value entry with a 69.9% margin of safety. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Boston Scientific Corp
HEALTHCARE · MEDICAL DEVICES · USA
Boston Scientific Corporation, doing business as Boston Scientific, is a manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology.
Edwards Lifesciences Corp
HEALTHCARE · MEDICAL DEVICES · USA
Edwards Lifesciences is an American medical technology company headquartered in Irvine, California, specializing in artificial heart valves and hemodynamic monitoring.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?